Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when FENC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsFennec Pharmaceuticals announces four PEDMARK abstracts accepted at 2026 ASCO conference
Filed April 22, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
low
Four research abstracts evaluating PEDMARK (sodium thiosulfate injection) accepted for presentation or publication at the American Society of Clinical Oncology Annual Meeting in Chicago, scheduled for 2026.
Item 8.01 verify on EDGAR → -
low
Press release issued April 21, 2026, announcing the ASCO abstract acceptances, providing visibility for the company's product at a major oncology conference.
Exhibit 99.1 view on EDGAR →
Summary
Fennec Pharmaceuticals filed a routine 8-K to announce that four research abstracts evaluating its drug PEDMARK were accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. PEDMARK is approved for reducing the risk of ototoxicity (hearing loss) in pediatric patients receiving cisplatin chemotherapy. While conference presentations can generate awareness among oncologists and researchers, abstract acceptances are common for marketed drugs and do not typically signal material business developments or near-term revenue impact.
Retail investors should watch for the actual presentation content when published, as data quality and physician reception could influence future prescribing patterns. This filing represents standard investor relations activity rather than a significant corporate event.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On April 21, 2026, Fennec Pharmaceuticals Inc. (the “Company”) issued a press release announcing that four abstracts evaluating PEDMARK® (sodium thiosulfate injection) were accepted for presentation or publication at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
The company announced that four research abstracts evaluating its drug PEDMARK will be presented or published at the American Society of Clinical Oncology Annual Meeting. This indicates ongoing clinical research and potential visibility for the company's product at a major oncology conference.
Event · Item 9.01 — Financial Statements and Exhibits
Fennec Pharmaceuticals filed an 8-K attaching a press release dated April 21, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
Exhibit 99.1
Press Release dated April 21, 2026
The 8-K references an attached press release dated April 21, 2026. The filing body itself contains no substantive disclosure; the material content would be in the exhibit, which is not provided in this input.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify